Consolidated Financial Result Briefing
for the nine months ended December 31, 2025
CYBERDYNE Inc. (Ticker Code: 7779)
February 12, 2026
Consolidated Nine months Results Summary (IFRS)
Consolidated revenue decreased due to the impact of the sale of subsidiaries in the previous fiscal year, while operating profit improved year on year
Profit before tax and profit attributable to owners of parent increased mainly due to gains on valuation of investment securities, resulting in an expansion of profitability
(Millions of yen) | FY2024 3Q | FY2025 3Q | '+/- | +/- % |
Revenue | 3,169 | 2,893 | △ 276 | △ 8.7% |
Operating profit (loss) | △ 708 | △ 274 | + 434 | - |
Profit (loss) before tax | △ 297 | 368 | + 665 | - |
Profit (loss) attributable to owners of parent | △ 384 | 190 | + 574 | - |
Revenue 2,893 Million
YoY -276 Million (-8.7%)
EMEA product rentals: +146 million yen (business +138 million yen, forex +8 million yen)
Domestic & APAC product rentals, etc.: +58 million yen (business +70 million yen, forex -12 million yen)
Treatment services: -119 million yen (business -94 million yen, forex -25 million yen)
Others: LeyLine -337 million yen, domestic -26 million yen
Operating profit (loss)
-274 Million
YoY +434 Million
EMEA product rentals: +99 million yen (business +96 million yen, forex +3 million yen)
Domestic & APAC product rentals, etc.: +104 million yen (business +112 million yen, forex -8 million yen)
Treatment services: +24 million yen (business +23 million yen, forex +1 million yen)
Others: LeyLine +121 million yen, domestic +44 million yen
R&D and head office expenses, etc.: +57 million yen
Profit (loss) before tax
368 Million
YoY +665 Million
Operating profit variance: +434 million yen
Gain on valuation of investment securities: +188 million yen
(FY2025 3Q YTD: +512 million yen vs. FY2024 3Q YTD: +324 million yen)
Finance costs -208 million yen (FY2025 3Q YTD: -256 million yen vs. FY2024 3Q YTD: -48 million yen)
FY2025 : Provision for doubtful accounts for LeyLine -252 million yen
Others (Gains related to CEJ Fund, etc.): +251 million yen
※ Exchange Rate USD/JPY: Mar 149.52 → Sep 148.88 → Dec 156.56 (YoY: Mar 151.41 → Sep 142.73 → Dec 158.18) EUR/JPY: Mar 162.08 → Sep 174.47 → Dec 184.33 (YoY: Mar 163.24 → Sep 159.43 → Sep 164.92)
Consolidated results: Revenue / Operating profit (Margin) (Nine-month period)
Product rentals and related services recorded year-on-year increases in both revenue and profit, driven by continued expansion in EMEA, APAC, and Japan Treatment services recorded a decrease in revenue but an increase in profit
(Millions of yen) | FY2024 3Q | FY2025 3Q | +/- | +/- % | |
Product rental | Revenue Operating Profit (Margin %) | 1,302 525 (40%) | 1,507 713 (47%) | +205 +188 (+7%) | + 16% + 36% |
Treatment service | Revenue Operating Profit (Margin %) | 1,345 △ 101 (△7%) | 1,226 △ 76 (△6%) | △ 119 +24 (+1%) | △ 9% - |
Others | Revenue Operating Profit (Margin %) | 522 △ 155 (△30%) | 160 10 (6%) | △ 362 +165 (+36%) | △ 69% - |
R&D expenses& Head office expenses | Adjusted amount | △ 978 | △ 921 | +57 | - |
Consolidated total(IFRS) | Revenue Operating Profit (Margin %) | 3,169 △ 708 (△22%) | 2,893 △ 274 (△9%) | △ 276 +434 (+13%) | △ 9% - |
Amount of operating profit or loss, which is revenue minus operating expenses, for each business
Adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.
Product rental：Revenue from rental of the Group's products（includes revenue from sales)
Treatment service：Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers)
Others：Revenue from the Group's other business (e.g. subsidiary in Sleeping App)
Revenue by geographical regions and type of transaction (Nine-month period)
(Unit : Millions of yen) Top︓2025 3Q YTD
(Bottom︓2024 3Q YTD)
Product rental Treatment Service Others
Total YoY
Revenue to sales ratio
Japan
728
(684)
91
(96)
160
(186)
979
(966)
+12
(+ 1%)
Domestic 34%
EMEA
348
(201)
54
(44)
-
(337) *
402
(582)
△ 180
(△ 31%)
APAC
403
(388)
-
(-)
-
(-)
403
(388)
+15
(+ 4%)
Foreign 66%
AMER
29
(28)
1,081
(1,205)
-
(-)
1,110
(1,233)
△ 123
(△ 10%)
Total
1,507
(1,302)
1,226
(1,345)
160
(522)
2,893
(3,169)
100%
YoY
+205
(+ 16%)
△ 119
(△ 9%)
△ 362
(△ 69%)
△ 276
(△ 9%)
EMEA :Europe, the Middle East and Africa APAC : Asia-Pacific *Excluding Japan AMER : North, Central and South America
* Impact of the sale of LeyLine GmbH (at the end of February 2025)
Rental revenue by each products (Nine-month period)
Domestic sales remained solid, supported by new installations of the Medical HAL Lower Limb Type(including small-size HAL) and HAL Single Joint Type
(Unit : Millions of yen) Top︓2025 3Q YTD (Bottom︓2024 3Q YTD) | Type of product | In Japan | Outside Japan | Total |
Medical HAL Lower Limb Type | 320 (278) | 537 (410) | 858 (687) | |
Cybernics Treatment Functional improvement | ||||
Non-medical HAL Lower Limb Type | 111 (118) | - (-) | 111 (118) | |
and regeneration | ||||
HAL Single Joint Type | 70 (65) | 113 (87) | 183 (151) | |
Well-being and care | HAL Lumbar Type | 66 (78) | 98 (66) | 164 (145) |
HAL Lumbar Type | 28 (29) | - (-) | 28 (29) | |
Labor Support | ||||
Mobile robot (CL02 etc.) | 65 (54) | - (-) | 65 (54) | |
Other（Acoustic X、Other products） | 69 (63) | 30 (55) | 99 (118) | |
Total | 728 (684) | 779 (618) | 1,507 (1,302) | |
Overseas sales also remained strong, supported by new installations of the Medical HAL Lower Limb Type, HAL Single Joint Type, and HAL Lumbar Type, mainly in EMEA (primarily Germany) and APAC (primarily Malaysia)
Disclaimer
This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.
Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.